Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain quality and best practices in content production [5]

Core Viewpoint - MiniMed has received FDA clearance for its next-generation insulin pump, MiniMed Flex, which is designed to be discreet and smartphone-controlled, enhancing the management of diabetes for users [1][3]. Product Features - MiniMed Flex is approximately half the size of the previous MiniMed 780G system and is designed to be screenless, making it more lifestyle-friendly [2][4]. - The pump utilizes the advanced SmartGuard adaptive algorithm with Meal Detection technology, which has shown clinical performance exceeding global Time in Range recommendations [2][5]. - It features a 300-unit insulin reservoir and is compatible with MiniMed's infusion set portfolio, including options that allow for up to 7 days of wear, significantly reducing the number of injections required [5][8]. Market Strategy - The launch will begin with a customer experience phase in spring 2026, followed by a broader commercial launch in summer 2026 [7]. - MiniMed has introduced the MiniMed Forward Program, allowing current users of the MiniMed 780G system to upgrade to the MiniMed Flex system at no additional cost [6][9]. Target Audience - The MiniMed Flex system is approved for individuals aged 7 and older with type 1 diabetes and for those 18 years and older with insulin-requiring type 2 diabetes [7]. Company Mission - MiniMed aims to improve the daily lives of people with diabetes through innovative technology that reduces the burden of diabetes management [3][11].

Core Viewpoint - MiniMed Group, Inc. has successfully closed its initial public offering (IPO) of 28 million shares at a price of $20.00 per share, raising approximately $538 million in net proceeds [1][1][1] Company Overview - MiniMed is a global leader in insulin delivery, providing advanced therapies for diabetes management in 80 countries [1][1] - The company has a full-stack, integrated ecosystem that includes insulin delivery systems, continuous glucose monitors (CGMs), algorithms, and a user-friendly app experience [1][1] IPO Details - The IPO shares began trading on the Nasdaq Global Select Market under the symbol "MMED" on March 6, 2026 [1][1] - Medtronic plc owns approximately 90.03% of MiniMed's common stock and aims to complete a separation through a split-off [1][1] - The net proceeds from the IPO will be used for general corporate purposes and to repay intercompany debt owed to Medtronic [1][1] Underwriters - The active bookrunners for the offering included Goldman Sachs & Co. LLC, BofA Securities, Citigroup, and Morgan Stanley [1][1] - Additional joint book running managers were Barclays, Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Evercore ISI, and Piper Sandler [1][1]

Core Viewpoint - MiniMed is set to go public with an IPO priced at $20 per share, aiming to raise up to $644 million, marking a significant step in Medtronic's strategy to spin off its diabetes business [2][3] Group 1: IPO Details - MiniMed plans to issue 28 million shares at a price of $20 each, with a potential maximum fundraising of $644 million if the underwriters' overallotment option is fully exercised [2] - The IPO is scheduled for March 9, 2026, on the NASDAQ under the ticker symbol MMED [3] - The initial price range was set between $25 and $28, indicating a notable decrease in the final pricing [3] Group 2: Company Background - MiniMed, established in the 1980s and acquired by Medtronic in 2001, has been a key player in the insulin pump market, focusing on diabetes technology [9] - The company specializes in developing insulin pump systems, automated insulin delivery systems, and related digital management platforms, maintaining a strong market share globally [9] Group 3: Market Dynamics - The insulin pump market is dominated by a few key players, including Medtronic, Insulet, and Tandem Diabetes Care [6] - Recent advancements in continuous glucose monitoring (CGM) technology have led to the integration of insulin pumps with CGM systems, creating automated insulin delivery systems, which is a significant trend in diabetes management [7] Group 4: Strategic Implications - Medtronic's decision to spin off its diabetes business is influenced by the increasing competition in the insulin pump market, allowing for independent financing and strategic flexibility [12] - The separation is expected to enhance the market's valuation of the diabetes business, reflecting a broader trend in the medical device industry where companies split off distinct business units for clearer valuation [12] Group 5: Insights for the Chinese Market - The diabetes device market in China is rapidly developing, with an increase in domestic insulin pump and CGM companies [15][16] - The trend towards automated closed-loop systems in diabetes management is gaining traction, indicating a growing and independent medical device sector [16] - Future competition in China will focus on the integration capabilities between insulin pumps, CGM, and algorithm platforms, rather than just individual devices [17]

Core Insights - Renaissance Capital specializes in pre-IPO research for institutional investors and investment banks, providing independent opinions and in-depth analysis on IPOs [1] Group 1: Company Overview - The firm manages two IPO-focused funds: the Renaissance IPO ETF (NYSE: IPO) and the Renaissance International IPO ETF (NYSE: IPOS) [1] - Individual investors can access a free overview of the IPO market through Renaissance Capital's website [1] Group 2: Services Offered - Renaissance Capital offers a pre-IPO research service that includes customizable financial models for all IPOs [1] - The service aims to provide institutional investors with comprehensive fundamental analysis [1]

Group 1 - MiniMed Group, Inc. (MMED) shares have been trading lower following its public offering due to a weak reception of Medtronic's (MDT) diabetes business [1] - The public response to the diabetes segment of Medtronic has been described as very soft, impacting MiniMed's stock performance [1] Group 2 - The service "Value in Corporate Events" offers insights on major corporate events such as earnings reports, M&A, and IPOs, aiming to provide actionable investment ideas [2]

Group 1 - MiniMed Group Inc., a subsidiary of Medtronic plc, has priced its initial public offering (IPO) at $20.00 per share for 28 million shares [1] - The shares are set to begin trading on the Nasdaq Global Select Market on March 6, 2026, under the symbol "MMED," with the offering expected to close on March 9, 2026 [1] - MiniMed has granted underwriters a 30-day option to purchase up to 4.20 million additional shares at the initial public price [2] Group 2 - After the IPO, Medtronic is expected to retain approximately 90.03% ownership of MiniMed, which will decrease to 88.70% if the underwriters fully exercise their over-allotment option [3] - MiniMed plans to use a portion of the net proceeds from the offering for general corporate purposes, with any remaining funds allocated to repaying intercompany debt owed to Medtronic and for additional consideration related to asset transfers during the separation [3]

Core Viewpoint - MiniMed Group, Inc. has announced the pricing of its initial public offering (IPO) at $20.00 per share, with 28,000,000 shares available for public trading on Nasdaq starting March 6, 2026 [1] Group 1: IPO Details - The IPO is expected to close on March 9, 2026, subject to customary closing conditions [1] - MiniMed has granted underwriters a 30-day option to purchase up to 4,200,000 additional shares at the initial price [1] - Upon completion of the IPO, Medtronic is expected to hold approximately 90.03% of MiniMed, or 88.70% if the over-allotment option is fully exercised [1] Group 2: Use of Proceeds - MiniMed intends to use a portion of the net proceeds for general corporate purposes [1] - The remainder will be used to repay intercompany debt owed to Medtronic and as additional consideration for certain assets transferred to MiniMed [1] Group 3: Company Background - MiniMed is a global leader in insulin delivery, providing integrated ecosystems for diabetes management in 80 countries [1] - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company addressing significant health challenges [1]

Core Viewpoint - Medtronic's diabetes care subsidiary, MiniMed Group, is initiating an IPO to become an independent entity on Nasdaq, offering approximately 28 million shares at an expected price range of $25 to $28 per share [1][2]. Group 1: IPO Details - MiniMed Group will trade under the ticker MMED and aims to raise funds to strengthen its balance sheet and cover general expenses [1][2]. - Post-IPO, Medtronic will retain 89% to 90% ownership of MiniMed Group, allowing for separate valuation of its diabetes portfolio and other business segments [2]. Group 2: Company Performance - Medtronic's stock has underperformed with a one-year performance of 4.6%, compared to the Vanguard Health Care Index Fund ETF's return of 7.99% [4]. - The company offers a dividend yield of 2.88%, appealing to income investors despite the performance trade-off [4][5]. Group 3: Valuation and Growth - Medtronic's stock trades at a forward P/E ratio of 23.29x, which is a moderate discount to its five-year average P/E of 25.18x, indicating stable growth prospects [5]. - The company is projected to grow profits by 7.95% in 2027, 7.74% in 2028, and 8.18% in 2029, with a payout ratio of 50% supporting continued dividend payments [5].

As filed with the Securities and Exchange Commission on February 27, 2026. Registration No. 333-292284 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification N ...